Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.33-
QQQ
716.250.03%
BTC/USD
78585.480.4494%
DIA
535.550.09%
GLD
409.230.08%
TLT
82.940.07%

HUTCHMED (China) Ltd

HCMNASDAQ
Trade with Public
Trade with Public
$12.38
-0.035-0.28%
At close: Aug 28, 5:00 PM EST
$12.31
-0.07-0.57%
After Hours: Aug 28, 5:09 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentCompareOptionsStock Report

HUTCHMED (China) Analyst Price Targets

Wall Street analyst price targets and consensus rating for HUTCHMED (China) (HCM).

Price Target Range — 6 Quarters

Analyst Consensus — 5 Analysts

3Buy
1Hold
1Sell
Consensus RatingBuy# Analysts5Avg. Consensus PT$23Upside to Avg. PT+85.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 23, 2026Goldman SachsPaul ChoiPT CutNeutral$16→$14
Jul 7, 2026B of A SecuritiesAlec StranahanPT CutBuy$20→$17
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Goldman Sachs Maintains Neutral on HUTCHMED (China), Lowers Price Target to $14

Goldman Sachs analyst Paul Choi maintains HUTCHMED (China) (NASDAQ:HCM) with a Neutral and lowers the price target from $16 to $14.
Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $17

B of A Securities analyst Alec Stranahan maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and lowers the price target from $20 to $17.
Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $20

B of A Securities analyst Dimple Gosai maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and lowers the price target from $21 to $20.
Benzinga Newsdesk

PRO
Morgan Stanley Downgrades HUTCHMED (China) to Underweight, Lowers Price Target to $13.75

Morgan Stanley analyst Jack Lin downgrades HUTCHMED (China) (NASDAQ:HCM) from Equal-Weight to Underweight and lowers the price target from $18 to $13.75.
Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Raises Price Target to $28

B of A Securities analyst Dimple Gosai maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and raises the price target from $27 to $28.
Benzinga Newsdesk

PRO
Goldman Sachs Maintains Neutral on HUTCHMED (China), Raises Price Target to $19

Goldman Sachs analyst Paul Choi maintains HUTCHMED (China) (NASDAQ:HCM) with a Neutral and raises the price target from $17 to $19.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved